Compare OXBR & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | TXMD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 19.7M |
| IPO Year | 2014 | N/A |
| Metric | OXBR | TXMD |
|---|---|---|
| Price | $1.41 | $1.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 19.3K | ★ 166.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $2,423,000.00 | ★ $2,796,000.00 |
| Revenue This Year | $497.99 | $427.09 |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | ★ N/A | $275.53 |
| Revenue Growth | N/A | ★ 75.19 |
| 52 Week Low | $1.12 | $0.70 |
| 52 Week High | $5.81 | $2.44 |
| Indicator | OXBR | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 58.07 |
| Support Level | $1.30 | $1.43 |
| Resistance Level | $1.42 | $1.75 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 77.33 | 46.27 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.